International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
Francesca Puledda, Simona Sacco, Hans‐Christoph Diener, Messoud Ashina, Haidar M. Al‐Khazali, Sait Ashina, Rami Burstein, Eric Liebler, Andrea Cipriani, Min Kyung Chu, Alexandra Cocores, Freda Dodd-Glover, Esme Ekizoğlu, David García‐Azorín, Carl H. Göbel, María Teresa Goicochea, Amr Hassan, Koichi Hirata, Jan Hoffmann, Bronwyn Jenkins, Katharina Kamm, Mi Ji Lee, Yu‐Hsiang Ling, Marco Lisicki, Daniele Martinelli, Teshamae Monteith, Raffaele Ornello, Aynur Özge, Mário Fernando Prieto Peres, Patricia Pozo‐Rosich, V.I. Romanenko, Todd J. Schwedt, Marcio Nattan Portes Souza, Tsubasa Takizawa, Gisela M. Terwindt, Janu Thuraiaiyah, Mansoureh Togha, Nicolas Vandenbussche, Shuu‐Jiun Wang, Shenguan Yu, Cristina Tassorelli
Abstract
Consistent with the mission of the International Headache Society (IHS) to improve migraine management worldwide, this document focuses on providing practical recommendations on the preventive pharmacological management of migraine. Due to the inconsistent availability of medications across different regions of the globe, these recommendations are categorized into two levels: Optimal and Essential. The Optimal level is intended for settings where most drug treatments are available. The Essential level is focused on countries where only the drugs listed in the World Health Organization (WHO) Model List of Essential Medicines (EML) are available